Showing results (1-10 of 374) with videos related to
Sort By:
Pageof 38
Clinical Transplantation|June 1, 1994
Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host diseaseJ Aschan, O RingdénBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2001
The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapseS Carlens, M Remberger, J Aschan, et al.European Journal of Haematology|August 1, 1992
A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipientsA Shanwell, S Larsson, J Aschan, et al.Leukemia|December 26, 2001
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantationJ Mattsson, M Uzunel, L Tammik, et al.Bone Marrow Transplantation|August 29, 2007
Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCTG Avetisyan, J Aschan, H Hägglund, et al.Bone Marrow Transplantation|September 22, 1999
Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemiaS Carlens, J Aschan, M Remberger, et al.Clinical Transplantation|June 8, 2001
Treatment of severe acute graft-versus-host disease with anti-thymocyte globulinM Remberger, J Aschan, L Barkholt, et al.Scandinavian Journal of Infectious Diseases|January 1, 1992
Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipientsJ Aschan, O Ringdén, P Ljungman, et al.Bone Marrow Transplantation|August 6, 2003
N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantationF Sjöö, J Aschan, L Barkholt, et al.Bone Marrow Transplantation|July 1, 1994
Individualized prophylaxis against graft-versus-host disease in leukemic marrow transplant recipientsJ Aschan, O Ringdén, E Andström, et al.Pageof 38